We believe the future of targeting AXL in AML involves a combinatorial approach with other targeted therapies, and our data further validate this idea and demonstrates the importance of combining AXL inhibition concurrently with FLT3 TKI to combat early adaptive resistance as well as later‐occurring acquired resistance. This evidence concerns the gene FLT3 and acute myeloid leukemia.